Amid a recall of its AirFit and AirTouch continuous positive airflow pressure (CPAP) devices, ResMed released its latest earnings report Wednesday afternoon. The San Diego-based medical device company ...
Needham analyst Mike Matson reiterated a Buy rating on ResMed Inc. (NYSE:RMD) with a price target of $180. ResMed registered a street-beating performance in the first quarter, where revenue increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback